| [1] |
Wang D, Xu T, Zhu H, et al. Primary malignant melanomas of the female lower genital tract: clinicopathological characteristics and management[J]. Am J Cancer Res, 2020, 10(12): 4017-4037.
|
| [2] |
Gadducci A, Carinelli S, Guerrieri ME, et al. Melanoma of the lower genital tract: prognostic factors and treatment modalities[J]. Gynecol Oncol, 2018, 150(1): 180-189. DOI: 10.1016/j.ygyno.2018.04.562.
|
| [3] |
Joste M, Dion L, Brousse S, et al. Vulvar and vaginal melanomas: a retrospective study spanning 19 years from a tertiary center[J]. J Gynecol Obstet Hum Reprod, 2021, 50(5): 102091. DOI: 10.1016/j.jogoh.2021.102091.
|
| [4] |
Ottaviano M, Giunta EF, Marandino L, et al. Anorectal and genital mucosal melanoma: diagnostic challenges, current knowledge and therapeutic opportunities of rare melanomas[J]. Biomedicines, 2022, 10(1): 150. DOI: 10.3390/biomedicines10010150.
|
| [5] |
Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma[J]. Cell, 2015, 161(7): 1681-1696. DOI: 10.1016/j.cell.2015.05.044. |
| [6] |
Beaudoux O, Oudart JB, Riffaud L, et al. Mutational characteristics of primary mucosal melanoma: a systematic review[J]. Mol Diagn Ther, 2022, 26(2): 189-202. DOI: 10.1007/s40291-021-00572-0.
|
| [7] |
|
| [8] |
Dobric EC, Vâjâitu C, Condrat CE, et al. Vulvar and vaginal melanomas-the darker shades of gynecological cancers[J]. Biomedicines, 2021, 9(7): 758. DOI: 10.3390/biomedicines9070758.
|
| [9] |
Shakeel O, Ullah F, Khalid N, et al. Malignant melanoma of the female genital tract: experience of an oncology center in Pakistan[J]. Cureus, 2020, 12(6)：e8484. DOI: 10.7759/cureus.8484.
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual[M]. 8th ed. New York: Springer, 2017: 1-1024.
|
| [14] |
Adams TS, Rogers LJ, Cuello MA. Cancer of the vagina: 2021 update[J]. Int J Gynaecol Obstet, 2021, 155(Suppl 1): 19-27. DOI: 10.1002/ijgo.13867.
|
| [15] |
Platt S, Wilson E, Pawade J, et al. Review of gynaecological malignant melanomas[J]. Obstet Gynaecol, 2020, 22(3): 199-207. DOI: 10.1111/tog.12666.
|
| [16] |
Wohlmuth C, Wohlmuth-Wieser I, May T, et al. Malignant melanoma of the vulva and vagina: a US population-based study of 1 863 patients[J]. Am J Clin Dermatol, 2020, 21(2): 285-295. DOI: 10.1007/s40257-019-00487-x.
|
| [17] |
Lewin J, Egbe A, Ellery P, et al. Female genital tract melanoma: 10 years of experience at a single tertiary center[J]. J Low Genit Tract Dis, 2021, 25(2): 142-145. DOI: 10.1097/lgt.0000000000000591.
|
| [18] |
Tian H, Wang X, Lian B, et al. Surgical outcomes of vaginal or cervical melanoma[J]. Front Surg, 2021, 8: 771160. DOI: 10.3389/fsurg.2021.771160.
|
| [19] |
Sinasac SE, Petrella TM, Rouzbahman M, et al. Melanoma of the vulva and vagina: surgical management and outcomes based on a clinicopathologic review of 68 cases[J]. J Obstet Gynaecol Can, 2019, 41(6): 762-771. DOI: 10.1016/j.jogc.2018.07.011.
|
| [20] |
Tian H, Wang X, Lian B, et al. Surgical outcomes of vaginal or cervical melanoma[J]. Front Surg, 2022, 8: 771160. DOI: 10.3389/fsurg.2021.771160.
|
| [21] |
Lopez S, Guerrisi R, Brusadelli C, et al. The role of sentinel lymph node mapping in lower genital tract melanoma[J]. Minerva Ginecol, 2020, 72(6): 384-390. DOI: 10.23736/s0026-4784.20.04628-6.
|
| [22] |
Yazdanfard NW, Mikkelsen LH, Behrendt N, et al. Vaginal melanoma in Denmark from 1980 to 2018: a population-based study based on genetic profile and survival[J]. Gynecol Oncol, 2022, 165(1): 53-59. DOI: 10.1016/j.ygyno.2022.01.028.
|
| [23] |
Murata H, Okonogi N, Wakatsuki M, et al. Long-term outcomes of carbon-ion radiotherapy for malignant gynecological melanoma[J]. Cancers (Basel), 2019, 11(4): 482. DOI: 10.3390/cancers11040482.
|
| [24] |
Komatsu-Fujii T, Nomura M, Otsuka A, et al. Response to imatinib in vaginal melanoma with KIT p．Val559Gly mutation previously treated with nivolumab, pembrolizumab and ipilimumab[J]. J Dermatol, 2019, 46(6): e203-e204. DOI: 10.1111/1346-8138.14763.
|
| [25] |
Lian B, Cui C, Song X, et al. Phase Ⅲ randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma[J]. J Clin Oncol, 2018, 36(15_suppl): 9589. DOI: 10.1200/JCO.2018.36.15_suppl.9589.
|
| [26] |
Yan X, Sheng X, Chi Z, et al. Randomized phase Ⅱ study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma[J]. J Clin Oncol, 2021, 39(8): 881-889. DOI: 10.1200/jco.20.00902.
|
| [27] |
Dimitriou F, Long GV, Menzies AM. Novel adjuvant options for cutaneous melanoma[J]. Ann Oncol, 2021, 32(7): 854-865. DOI: 10.1016/j.annonc.2021.03.198.
|
| [28] |
Swetter SM, Thompson JA, Albertini MR. NCCN Clinical Practice Guidelines in Oncology. Melanoma: cutaneous (version 2.2022)[EB/OL]. (2022-01-27)[2022-07-16].
URL
|
| [29] |
Wilhite A, Wu S, Xiu J, et al. Too much skin in the game? A paradigm shift in our understanding of vulvar and vaginal melanomas as distinct tumor types compared with cutaneous melanomas[J]. Gynecol Oncol, 2021, 162(suppl 1): S33-S34. DOI: 10.1016/s0090-8258(21)00708-3.
|
| [30] |
Wilhite A, Wu S, Zeng J, et al. P28 investigating molecular profiles of subtypes of mucosal melanomas: is vulvovaginal melanoma a distinct entity？[J]. Gynecol Oncol, 2022, 165(suppl 1): S20-S21. DOI: 10.1016/s0090-8258(22)00373-0.
|
| [31] |
Quéreux G, Wylomanski S, Bouquin R, et al. Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas？[J]. J Eur Acad Dermatol Venereol, 2018, 32(1): e39-e40. DOI: 10.1111/jdv.14486.
|
| [32] |
Yu Y, Tse KY, Lee HHY, et al. Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases[J]. Mod Pathol, 2020, 33(1): 138-152. DOI: 10.1038/s41379-019-0345-2.
|
| [33] |
Indini A, Di Guardo L, Cimminiello C, et al. Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience[J]. J Gynecol Oncol, 2019, 30(6): e94. DOI: 10.3802/jgo.2019.30.e94.
|
| [34] |
Herrera FG, Ronet C, Ochoa de Olza M, et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy[J]. Cancer Discov, 2022, 12(1): 108-133. DOI: 10.1158/2159-8290.CD-21-0003.
|
| [35] |
Shi K, Zhang B, Kong BY, et al. Distinct genomic features in a retrospective cohort of mucosal, acral and vulvovaginal melanomas[J]. J Am Acad Dermatol, 2019: S0190-9622(19)32374-6. DOI: 10.1016/j.jaad.2019.07.017.
|
| [36] |
Zarei S, Voss JS, Jin L, et al. Mutational profile in vulvar, vaginal, and urethral melanomas: review of 37 cases with focus on primary tumor site[J]. Int J Gynecol Pathol, 2020, 39(6): 587-594. DOI: 10.1097/pgp.0000000000000636.
|
| [37] |
Wang HY, Wu XY, Zhang X, et al. Prevalence of NRAS mutation, PD-L1 expression and amplification, and overall survival analysis in 36 primary vaginal melanomas[J]. Oncologist, 2020, 25(2): e291-e301. DOI: 10.1634/theoncologist.2019-0148.
|